Sanofi Presents P-III (LIBERTY ASTHMA EXCURSION) trial Results of Dupixent (dupilumab) for Moderate to Severe Asthma at ERS 2022
Shots:
- The P-III (LIBERTY ASTHMA EXCURSION) trial evaluates Dupixent (100/200mg, q2w or 300mg, q4w) as a maintenance therapy when added to other asthma medications in 365 children with uncontrolled mod. to sev. Asthma for 52wks.
- The results showed a sustained improvement in lung function @52wks., a low rate of asthma attacks with an avg. of 0.118-0.124 events/year over 2.16-2.56 events/year at baseline along with a consistent safety profile for ≥2yrs. in children aged 6 to 11yrs.
- Children who moved from PBO in the pivotal trial to Dupixent in the extended study had improved lung function @2wks. by 8.71 percentage points. The safety results were consistent with the known safety profile of Dupixent in its approved respiratory indications
Ref: Globe Newswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
